All conditions

Schizophrenia

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

3196
Trials on record
311
Recruiting now
4
Australian sites
30
Phase 3 trials
12
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Schizophrenia →

Get alerts when Schizophrenia trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Schizophrenia

Schizophrenia is a mental health condition that affects the way a person experiences reality. People with schizophrenia may hear, see, or believe things that others around them do not, which can feel very real and sometimes frightening. They may also find it harder to think clearly, concentrate, or feel motivated in the ways they used to. These experiences are caused by changes in how the brain processes information, and they are not a sign of weakness or poor character. It is also important to know that schizophrenia is not the same as having a "split personality," which is a common but inaccurate idea many people have seen in films or television.

Schizophrenia is more common than many people realise. In Australia, it affects roughly one in every hundred people at some point in their life, meaning hundreds of thousands of Australians and their families are touched by this condition. It can appear in people of any background, and it most often first shows up in late adolescence or early adulthood, though it can develop at other ages too. Receiving a diagnosis can feel overwhelming, but you are far from alone, and support services exist right across the country.

Treatment in Australia generally involves a combination of medication and psychological and social support, coordinated by a mental health team that may include psychiatrists, GPs, psychologists, and social workers. Medication can help reduce or manage symptoms for many people, while other supports focus on daily living, relationships, and staying connected to community. Many people with schizophrenia live full and meaningful lives with the right support in place.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Schizophrenia in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Schizophrenia

12 medicines listed on the PBS for Schizophrenia. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 12 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Amisulpride Amisulpride Sandoz Pharma, Solian Solution Schizophrenia AU$4.75 Streamlined authority
Aripiprazole Abilify Maintena, Aripiprazole GH, Abilify Asimtufii Schizophrenia AU$23.55 Streamlined authority
Asenapine Saphris Schizophrenia AU$114.95 Streamlined authority
Brexpiprazole Rexulti Schizophrenia AU$116 Streamlined authority
Cariprazine Reagila Schizophrenia AU$82.76 Streamlined authority
Clozapine Clopine 200, Clozaril 25, Clopine 50 +3 more Schizophrenia AU$27.75 Streamlined authority
Lurasidone Lurasidone Lupin Schizophrenia AU$14.52 Streamlined authority
Olanzapine APO-Olanzapine ODT, Zyprexa, Zyprexa Zydis +1 more Schizophrenia AU$3.08 Streamlined authority
Paliperidone Invega Trinza, Invega Hafyera, Invega Sustenna +1 more Schizophrenia AU$39.09 Streamlined authority
Quetiapine Seroquel XR, Seroquel Schizophrenia AU$4 Streamlined authority
Risperidone APO-Risperidone, Risperdal, Risperdal Consta +1 more Schizophrenia AU$4 Streamlined authority
Ziprasidone ZIPROX Schizophrenia AU$27.51 Streamlined authority

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Schizophrenia currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Schizophrenia.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Schizophrenia by country. Australia is highlighted.

Showing the top 10 of 48 countries with trial sites.

If you need support right now

Voxsanity is not an emergency or crisis service, and this page is not medical advice. If you or someone else is in immediate danger, call 000. Australian crisis support lines are below. If you are outside Australia, see our helpful links page for support in your country.

  • Lifeline (24/7 crisis support): 13 11 14
  • Beyond Blue: 1300 22 4636
  • 13YARN (Aboriginal & Torres Strait Islander crisis support, 24/7): 13 92 76
  • Suicide Call Back Service: 1300 659 467
  • SANE Australia: 1800 187 263
  • Emergency: 000

Find a service or provider through official directories:

Questions you could bring to a GP or specialist:

  • What are the treatment options for my situation, and what does each involve?
  • Is a clinical trial something worth considering for me, and how would I be assessed for one?
  • What support is available while I wait for an appointment or a decision?

Clinical trials for Schizophrenia

Showing 311 of 311 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT04113993 · The Alfred Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2026
🇦🇺 AU

**Who might be able to join this trial:** - People who are currently in good physical health - People who have a current diagnosis of schizophrenia or a related condition, as defined by DSM-V criteria - People aged between 18 and 65 years old - People who are able to understand and agree to take part in the trial (giv...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT05982158 · Swinburne University of Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇦🇺 AU

**Who might be able to join this trial:** - People who have been diagnosed with a schizophrenia-related condition, or a mood disorder with psychotic symptoms, confirmed through a structured diagnostic interview - People who are currently hearing voices (auditory verbal hallucinations), at a level measured as moderatel...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT06947941 · Bristol-Myers Squibb Phase 3 · 5 countries Recruiting
Recruiting Phase 3 Est. completion 21 February 2028
🇦🇺 AU🇨🇦 CA🇯🇵 JP🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You must be between 55 and 90 years old at the time of your first screening visit. - You must have been diagnosed with Alzheimer's disease based on the most recent 2024 Alzheimer's Association guidelines. - You must have had a brain scan (MRI or CT) within the past 5 years, taken...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07424404 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company Phase 3 · 11 countries Recruiting
Recruiting Phase 3 Est. completion 8 March 2030
🇦🇷 AR🇦🇺 AU🇨🇦 CA🇫🇷 FR🇩🇪 DE🇭🇺 HU🇯🇵 JP🇵🇱 PL +3 more

**Who might be able to join this trial:** - You must have completed the full treatment period of one of three related studies (CN0120020, CN0120044, or CN0120045) without experiencing a side effect that the study doctor considered a serious safety concern. **Who may not be able to join:** - People who have a history o...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06818227 · Assistance Publique Hopitaux De Marseille Not Applicable · 1 country Not Yet Recruiting
Not Yet Recruiting Not Applicable Est. completion 21 September 2026
🇫🇷 FR

**Who might be able to join this trial:** - You currently live in France - You are between 18 and 65 years old at the time of joining the trial - You are receiving care at one of the 12 participating psychiatric facilities involved in the study - You have a confirmed diagnosis of a schizophrenia-related condition (such...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01392885 · BC Mental Health and Addictions Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇨🇦 CA

Who might be able to join this trial: - People aged between 18 and 45 years old - People who are able to give written consent in English - People who are currently taking prescribed medications may still be eligible - People who have been diagnosed with schizophrenia or schizoaffective disorder (as defined by DSM-IV cr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01409109 · University of Texas Southwestern Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2029
🇺🇸 US

Who might be able to join this trial: **People with schizophrenia or a related condition:** - People who have been formally diagnosed with schizophrenia or schizoaffective disorder (based on standard diagnostic guidelines known as DSM-IV-TR) - People who are able to understand and agree to take part in the study on th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01730781 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are male and between 18 and 55 years old - If joining as a cannabis user: you are willing to stop using cannabis for four weeks - If joining as someone with schizophrenia: you have been formally diagnosed with schizophrenia or schizoaffective disorder (based on DSM-IV-TR...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02455193 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with schizophrenia or schizoaffective disorder - People who are between 21 and 70 years old - People who are currently prescribed one of these medications: olanzapine, risperidone, clozapine, or haloperidol — or who are not currently taking any anti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02639702 · Centre for Addiction and Mental Health Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2026
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with schizophrenia or schizoaffective disorder based on a specific set of standard diagnostic guidelines (called DSM-IV criteria) - People who are being treated as outpatients (not currently staying in a hospital) - People who are 18 years of age or...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT02640911 · Shanghai Mental Health Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2030
🇨🇳 CN

Who might be able to join this trial: - You are 18 years old or older, and can be either male or female, whether or not you are currently staying in hospital - You have been diagnosed with schizophrenia according to a standard set of medical guidelines called DSM-IV - You are able to communicate effectively, fill out s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02670447 · Centre Hospitalier Universitaire de Saint Etienne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2030
🇫🇷 FR

**Who might be able to join this trial:** - Men and women between 18 and 35 years old - People who are members or beneficiaries of a social security scheme - Women for whom a reliable form of contraception is in place and who have a negative pregnancy test result - People who have been diagnosed with schizophrenia, sch...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02916810 · The University of Texas Health Science Center, Houston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2029
🇺🇸 US

**Who might be able to join this trial:** - People aged between 18 and 50 years, of any gender. - People who are able to give written informed consent. - People who have been diagnosed with a schizophrenia-spectrum disorder and who score above 10 on a consent-related assessment called the Evaluation to Sign Consent (E...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03332966 · Finnish Institute for Health and Welfare Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇫🇮 FI

Who might be able to join this trial: - People who are starting care at an adolescent mental health clinic Who may not be able to join: - People who have previously been diagnosed with a psychotic disorder Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03495024 · Corporal Michael J. Crescenz VA Medical Center Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 April 2020
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with schizophrenia or schizoaffective disorder, and your condition is currently stable - You have been diagnosed with a movement disorder called tardive dyskinesia (TD), assessed using a specific medical checklist (confirm with trial site) - You curren...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT03525054 · University Hospital, Brest Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 May 2030
🇫🇷 FR

Who might be able to join this trial: - People aged 15 to 30 years old (both minors and adults) - People who have reported suicidal thoughts, a suicidal act, or suicidal behaviour that has affected their emotional, social, or work life - People who are covered by a health insurance or social security scheme - People wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03649581 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 2 February 2027
🇫🇷 FR

**Who might be able to join this trial:** *For both patients and people in the control group:* - People who are willing to take part and have signed the required consent form - People who are male or female *For patients only:* - People who are covered by health insurance - People who have been diagnosed with schizop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03794076 · Vishwajit Nimgaonkar, MD PhD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to give written agreement to take part in the trial. - You are between 18 and 60 years old (any gender). - You have been diagnosed with schizophrenia or schizoaffective disorder according to standard diagnostic guidelines (DSM-5). - You have been taki...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03817502 · Gedeon Richter Plc. Phase 3 · 8 countries Recruiting
Recruiting Phase 3 Est. completion 15 December 2026
🇧🇬 BG🇨🇴 CO🇲🇽 MX🇷🇴 RO🇷🇺 RU🇷🇸 RS🇺🇦 UA🇺🇸 US

**Who might be able to join this trial:** - People who have been given a primary diagnosis of schizophrenia according to standard diagnostic guidelines (DSM-5). - People whose schizophrenia diagnosis has been confirmed by a trained clinician using a structured interview tool (called the K-SADS-PL) at the first study v...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03906435 · University of Texas Southwestern Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - The baby must have been born at Parkland Hospital - The baby's mother (and/or father) must speak English or Spanish - The baby must have been born at 30 weeks and 6 days of pregnancy or earlier (very premature) - The baby must have survived to 33 weeks of gestational age (the equ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03971487 · The Methodist Hospital Research Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People of any gender between 18 and 35 years old. - People who have been diagnosed with a Schizophrenia Spectrum Disorder (a type of psychotic illness) lasting at least six months, confirmed using a standard psychiatric interview tool. - People whose symptom scores on a stan...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03995121 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are willing and able to give written consent to take part voluntarily - Men and women between the ages of 18 and 65 (inclusive) Who may not be able to join: - People who cannot have an MRI scan due to metal in their body, or who experience severe anxiety in enclosed s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04004364 · Northwell Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2025
🇺🇸 US

"Who might be able to join this trial: - People who are enrolled in the CSC (Coordinated Specialty Care) program (confirm with trial site) Who may not be able to join: - There are no listed exclusion criteria for this trial Important: Always verify eligibility with the trial site directly before applying."

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04033679 · Centre for Addiction and Mental Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇨🇦 CA

**Who might be able to join this trial:** - You can be male or female, of any race or background - You must be 18 years of age or older, and can be either a hospital inpatient or an outpatient - You must have a diagnosis of schizophrenia or schizoaffective disorder (based on standard diagnostic guidelines called DSM-V)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04038840 · Davidzon, Guido, M.D. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2025
🇺🇸 US

**Who might be able to join this trial:** - People between 18 and 65 years of age - For people with schizophrenia: those who have been on a stable medication routine for at least two weeks before the study visit - For people with schizophrenia: those with a diagnosed schizophrenia, schizophreniform disorder, or schizoa...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04046497 · Northwell Health Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 November 2024
🇺🇸 US

Who might be able to join this trial: - You are currently taking part in a Coordinated Specialty Care (CSC) program (a type of early mental health support program) - You have been prescribed an antipsychotic medication that you take by mouth (a pill or liquid, not an injection) Who may not be able to join: - There are...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04159662 · The Royal Ottawa Mental Health Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇨🇦 CA

**Who might be able to join this trial:** - People aged between 18 and 60 years old - People whose IQ scores above 70, as measured by a standard intelligence test called the WASI - People who can read and speak fluent English - People who have been diagnosed with schizophrenia, schizoaffective disorder, or major depres...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04226898 · Sheppard Pratt Health System Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged between 18 and 65 years old (inclusive). - People who are able to give written consent to participate. - People who have been formally diagnosed with schizophrenia or schizoaffective disorder, confirmed using a structured diagnostic interview based on the DSM-5 (...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04237155 · Hôpital le Vinatier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇫🇷 FR

**Who might be able to join this trial:** - Men and women between 18 and 45 years old - People who speak French as their first language - People who have normal vision, or vision that is fully corrected with glasses or contact lenses - People who have completed at least 8 years of education - People who have agreed to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04267003 · University of California, Davis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇺🇸 US

**Who might be able to join this trial:** - People who can speak and understand English well enough to complete thinking and memory tasks - People who are able to give their own informed consent to take part **For people with schizophrenia specifically, the following also apply:** - People who have been diagnosed wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04278339 · Centre Hospitalier Universitaire de Nice Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇫🇷 FR

Who might be able to join this trial: - People who have a good command of the French language - People who are right-handed - (For patients specifically) People who have been diagnosed with schizophrenia or schizoaffective disorder, and whose condition has been assessed as stable by their treating psychiatrist Who may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04296604 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇺🇸 US

Who might be able to join this trial: - Adults between 18 and 65 years old, both male and female, who are being treated as outpatients (not staying overnight in a hospital) - People who have been diagnosed with one of the following conditions, based on recognised diagnostic guidelines (DSM-5): traumatic brain injury, m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04300946 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇫🇷 FR

**Who might be able to join this trial:** - People aged between 18 and 60 years old, male or female - People who are enrolled in a social health insurance scheme, either as a primary member or as a dependent - People who have read, dated, and signed a consent form agreeing to take part - Women who could become pregnant...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04366518 · Yale University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 August 2032
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 65 years old - You speak English - You are right-handed - You have been diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, schizotypal disorder, or brief psychotic disorder - You hear voices (auditory hallucinations) at least...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT04368039 · Nicholas Breitborde Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 7 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a schizophrenia-spectrum disorder, or a mood disorder that includes psychotic features, confirmed through a structured diagnostic interview - People whose psychotic symptoms first began less than 5 years ago, as measured by a specific asse...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04370730 · Assistance Publique - Hôpitaux de Paris Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇫🇷 FR

**Who might be able to join this trial:** **For the young patient:** - Children and young people aged 7 to 20 years old, whose psychotic disorder first started between the ages of 7 and 17 - Currently receiving hospital or outpatient care for a psychotic episode, whether recent or ongoing - Has been diagnosed with one...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04411225 · University of California, San Diego Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have experienced a first episode of psychosis that began within the last 2 years, or who have an attenuated (mild/early) psychosis syndrome, and whose condition has been stabilised with treatment for at least 8 weeks - People who have been clinically stable and no...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04414215 · University of Georgia Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with schizophrenia or schizoaffective disorder according to current standard diagnostic guidelines (DSM-5) - People aged between 18 and 60 years old - People who speak English - People whose level of intellectual functioning before their illness was...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04432116 · Institut National de la Santé Et de la Recherche Médicale, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 May 2027
🇫🇷 FR

**Who might be able to join this trial:** - People aged between 18 and 60 years old, male or female - People who are covered by a social health insurance scheme - People who have read, dated, and signed a consent form agreeing to take part - Women who could become pregnant must have a negative pregnancy test and use e...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04478838 · Centre for Addiction and Mental Health Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 September 2027
🇨🇦 CA

**Who might be able to join this trial:** - People who have been diagnosed with a Schizophrenia Spectrum or Other Psychotic Disorder, confirmed using a standard diagnostic tool called the MINI - People aged 18 or older - Women who could become pregnant must be using a reliable form of contraception and must have a neg...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04580134 · University of Texas Southwestern Medical Center Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 60 years old - You are any gender, race, or ethnicity - You are able to read, speak, and understand English - You are in a stable condition medically - You have been diagnosed with schizophrenia, schizoaffective disorder, or bipolar I disorder with psyc...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04629352 · National Institute of Mental Health and Neuro Sciences, India Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇮🇳 IN

Who might be able to join this trial: - People who have been diagnosed with schizophrenia or schizoaffective disorder, based on standard diagnostic guidelines (DSM-5) - People who experience auditory verbal hallucinations (hearing voices) that are considered clinically significant - People who are right-handed - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04655235 · RWTH Aachen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇩🇪 DE

Who might be able to join this trial: **For patients:** - You have been diagnosed with schizophrenia according to standard diagnostic guidelines (DSM-5) - You are between 18 and 80 years old - You are able to fully understand and agree to take part in the study on your own **For healthy participants (people without s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04730518 · Charite University, Berlin, Germany Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2025
🇩🇪 DE

**Who might be able to join this trial:** - You can be male or female - You are currently receiving care as an inpatient on a psychiatric ward for psychosis, or attending a day clinic for social and psychiatric support - You are 18 years old or older - You have been diagnosed with a schizophrenia-spectrum disorder (a g...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04745143 · China Medical University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇹🇼 TW

Who might be able to join this trial: - You have been officially diagnosed with schizophrenia according to standard psychiatric guidelines (DSM-5). - You either refuse to take antipsychotic medications or cannot tolerate them because they don't work well enough or cause bad side effects. - Your schizophrenia symptoms a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04763655 · Northwell Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇺🇸 US

**Who might be able to join this trial:** - You currently experience moderate to severe symptoms such as hallucinations, unusual beliefs, suspicion of others, or disorganized thinking (as measured by a standard rating scale) - You have tried at least one antipsychotic medication for at least 6 weeks and it did not work...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04789915 · Bjorn H. Ebdrup Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2025
🇩🇰 DK

**Who might be able to join this trial:** **For people experiencing a first episode of psychosis:** - People who are experiencing their first episode of psychosis and have not recently taken antipsychotic medication (see exclusion details below) - People who have been diagnosed with a psychotic disorder such as schizo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04807530 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇺🇸 US

**Who might be able to join this trial:** **All participants:** - People who are in good general physical health - People whose first language is English - People who do not have a neurological disorder - People who meet the medical requirements for having an MRI scan - People who do not currently have an alcohol or s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04871048 · Centre Hospitalier Universitaire de Saint Etienne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇫🇷 FR

Who might be able to join this trial: - You have been diagnosed with schizophrenia based on standard medical guidelines, and your psychiatric medications have not changed in at least 4 weeks - You have a moderate to severe cannabis use problem (as defined by standard medical guidelines) and have used cannabis in the pa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04887792 · Vishwajit Nimgaonkar, MD PhD Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 30 December 2027
🇮🇳 IN🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 55 years of either gender who have provided written agreement to take part - People whose symptoms score above a certain threshold on a standard psychiatric scale (called the PANSS), with at least one significant positive symptom such as hallucinations or de...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04917302 · China Medical University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇹🇼 TW

**Who might be able to join this trial:** - You have been officially diagnosed with schizophrenia according to standard psychiatric guidelines (DSM-5) - Your symptoms have not responded well enough to at least two different antipsychotic medications - Your symptoms have been stable (without major changes) for at least...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04940663 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are between 18 and 55 years old - People who have experienced a psychotic disorder or a mood disorder **Who may not be able to join:** - People who have a neurological disorder, or who have had a substance use problem in the past 6 months - People who are not prof...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04945278 · University Hospital, Brest Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇫🇷 FR

**Who might be able to join this trial:** **For patients:** - People aged between 15 and 25 years old - People who meet specific "Ultra High Risk" criteria as assessed using recognised clinical tools (confirm with trial site) - People who are willing to sign a consent form — for those under 18, a parent or guardian mu...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04959201 · China Medical University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇹🇼 TW

Who might be able to join this trial: - People who have been formally diagnosed with schizophrenia according to standard diagnostic guidelines (DSM-5). - People who still have symptoms of schizophrenia but whose condition has been stable (no major changes) for at least 3 months, and whose antipsychotic medication dose...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05025605 · BioXcel Therapeutics Inc Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 July 2027
🇺🇸 US

Who might be able to join this trial: - Young people aged 10–17 years old who have been diagnosed with bipolar disorder, or aged 13–17 years old who have been diagnosed with schizophrenia. - Patients who are showing signs of significant agitation (restlessness or emotional distress), as measured by a specific rating sc...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05036590 · Hôpital le Vinatier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇫🇷 FR

Who might be able to join this trial: - You are 18 years old or older - You are a close family member (such as a parent, brother, sister, or child) or the spouse of someone with schizophrenia or a first episode of psychosis - You are the main caregiver for that person - You agree to take part in the study Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05052853 · China Medical University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇹🇼 TW

**Who might be able to join this trial:** - People who show signs of a "prodromal" (early warning) phase of psychosis, meaning they experience at least one of the following: mild or partial psychotic symptoms (such as unusual thoughts or perceptions), brief episodes of psychotic symptoms that go away on their own, or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05074732 · Health Service Executive, Ireland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇮🇪 IE

Who might be able to join this trial: - People who were admitted to the National Forensic Mental Health Service (NFMHS) in Ireland at any point from 1st December 2019 until 7 years after the service moves to its new location at Portrane, North Dublin, Ireland. Who may not be able to join: - There are no listed exclusi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05102929 · Fabio Ferrarelli Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 40 years old - You have been diagnosed with a schizophrenia-related mental health condition (as defined by standard psychiatric guidelines) - Your psychosis symptoms or treatment began less than three years ago **Who may not be able to join:** - You ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05127278 · King's College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇬🇧 GB

Who might be able to join this trial: - People who are between 12 and 35 years of age - People who are able to provide informed consent (agreement to participate after being given information about the trial) - People who have not previously been diagnosed with a psychotic disorder Who may not be able to join: - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05142735 · Centre for Addiction and Mental Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇨🇦 CA

**Who might be able to join this trial:** - People who meet specific criteria for being at risk of developing psychosis, as assessed through a structured clinical interview called the SIPS. - People who are able to understand and agree to take part in the study on their own. - Women who are not able to become pregnant...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05157620 · VA Office of Research and Development Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 70 years - People who are able to provide written consent to participate - People who have been diagnosed with schizophrenia, schizoaffective disorder, or bipolar 1 disorder (as defined by DSM-5 standards) - People with one of those diagnoses who also have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05159349 · Shanghai Mental Health Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇨🇳 CN

Who might be able to join this trial: - People who are registered in the Shanghai Mental Health Information Management System. - People who have been diagnosed with schizophrenia according to standard international diagnostic guidelines (ICD-10 or ICD-11). - People whose schizophrenia diagnosis was made within the last...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05184335 · Reviva Pharmaceuticals Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2025
🇺🇸 US

**Who might be able to join this trial:** - You are male or female, between 18 and 65 years old - You are able to read, understand, and sign a consent form approved by an ethics committee before any screening begins - You have been diagnosed with schizophrenia **Who may not be able to join:** - You have a history of n...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05185128 · Loma Linda University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - Adolescents between 12 and 18 years of age - People who have a confirmed diagnosis of Autism Spectrum Disorder (ASD), assessed using two specific diagnostic tools (confirm with trial site) - People who have been diagnosed with a schizophrenia-related condition, such as schizo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05208190 · New York State Psychiatric Institute Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been formally diagnosed with schizophrenia or schizoaffective disorder using a structured clinical interview - People who have committed at least one act of violence (minor or serious) in the past six months, as measured by a specific assessment tool - People...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05240976 · China Medical University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2027
🇹🇼 TW

**Who might be able to join this trial:** - People who have been formally diagnosed with schizophrenia according to standard psychiatric guidelines (DSM-5) - People whose schizophrenia did not respond well to at least two different standard antipsychotic medications before trying clozapine - People who have been takin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05276050 · The University of Texas Health Science Center, Houston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 July 2026
🇺🇸 US

Who might be able to join this trial: - People aged between 22 and 65 years, of any gender - People who are able to read and sign a consent form agreeing to take part - People who have smoked for at least one year and have smoked an average of 5 or more cigarettes per day over the past 4 weeks - People who have been di...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05282277 · University of North Carolina, Chapel Hill Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are willing to sign and date a consent form agreeing to take part in the study - You are willing to follow all study procedures, make lifestyle adjustments, and be available for the full length of the study - You are a woman between 44 and 55 years old, not currently taki...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05284721 · Washington State University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2025
🇺🇸 US

Who might be able to join this trial: - You are 18 years old or older - You identify as Black/African American - You have a family member or loved one who has been identified as being at risk for psychosis, based on their score on a specific screening questionnaire (confirm with trial site) Who may not be able to join...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05296720 · Centre Psychothérapique de Nancy Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇫🇷 FR

Who might be able to join this trial: - People who are male or female - People aged between 18 and 60 years old (inclusive) - People who have read, dated, and signed the consent form before any trial procedures begin (or whose legal guardian has done so, if applicable) - People who are enrolled in, or covered by, a soc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05299749 · Boston VA Research Institute, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with schizophrenia or schizoaffective disorder based on standard medical guidelines (DSM-5) - You hear voices (auditory hallucinations) that have not gotten better with medication, as confirmed by your medical records and a structured interview Who may no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05304767 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company Phase 3 · 9 countries Recruiting
Recruiting Phase 3 Est. completion 19 March 2026
🇧🇬 BG🇨🇿 CZ🇮🇳 IN🇯🇵 JP🇵🇱 PL🇷🇴 RO🇷🇸 RS🇬🇧 GB +1 more

**Who might be able to join this trial:** - People who were aged 18 to 65 years old at the time they were enrolled in the earlier related study (KAR-012). - People who successfully completed the full treatment period of the earlier study, KAR-012. - People who, in the doctor's opinion, followed all the procedures requ...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05316883 · Jimmi Nielsen Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2029
🇩🇰 DK

**Who might be able to join this trial:** - You have been diagnosed with schizophrenia, chronic paranoid psychosis, schizoaffective disorder, or another non-organic psychosis (based on recognised medical diagnosis codes) - You are between 18 and 65 years old - You are legally able to make your own decisions and give co...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05325645 · Otsuka Pharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2026
🇯🇵 JP

Who might be able to join this trial: - People who are at least 18 years old and under 65 years old at the time of signing the consent form - People who have been diagnosed with schizophrenia (specifically, multiple episodes and currently in an acute episode) based on a recognised diagnostic standard, confirmed by a st...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05329363 · University Hospital, Tours Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇫🇷 FR

**Who might be able to join this trial:** - People aged between 18 and 65 years old - People who have been diagnosed and officially recorded as having schizophrenia or schizoaffective disorder - People who have been diagnosed and officially recorded as having a delusional disorder - People who are able to communicate v...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05340348 · University Hospital, Brest Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 July 2032
🇫🇷 FR

**Who might be able to join this trial:** - People aged 15 to 30 who have been assessed at the CEVUP clinic (a specialist clinic for psychological vulnerability) and are receiving care at a psychiatry centre following a first episode of psychosis (their first hospitalisation for this) - People who have been referred t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05343598 · Mclean Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with schizophrenia or schizoaffective disorder **Who may not be able to join:** - People who have had a substance use disorder in the past 3 months - People who are ambidextrous (able to use both hands equally well) - People who have a history...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05349513 · Centre Hospitalier Henri Laborit Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 to 65 years old (inclusive) - People who have been diagnosed with schizophrenia or schizoaffective disorder, as defined by a standard psychiatric diagnostic guide (DSM-5) - People currently receiving care at a specific type of rehabilitation and therapeutic care ce...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05365347 · Nova Scotia Health Authority Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇦 CA

Who might be able to join this trial: - People aged 16 to 35 years old who are receiving care through Early Intervention Services for Psychosis in Nova Scotia - People who have been living with a psychotic illness for less than 5 years - People who have been diagnosed with a psychotic spectrum condition, such as schizo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05389787 · Northwell Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 to 60 years old, of any gender - People who have been diagnosed with a schizophrenia spectrum disorder according to standard diagnostic guidelines (DSM-5) - People who are able to understand and agree to participate in the trial on their own behalf Who may not be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05435300 · Centre for Addiction and Mental Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇨🇦 CA

**Who might be able to join this trial:** - You are male or female, of any race or ethnicity - You are 18 years of age or older, whether currently in hospital or receiving care as an outpatient - You have been diagnosed with schizophrenia or schizoaffective disorder (according to DSM-V standards) - You are able to unde...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05457140 · Rady Pediatric Genomics & Systems Medicine Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇺🇸 US

**Who might be able to join this trial:** - You are a child or teenager who has been admitted to Rady Children's CAPS unit and is showing symptoms of psychosis for the first time. - You are a biological parent of a child or teenager already enrolled in this study (for the purpose of genetic comparison testing). **Who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05500001 · University of Alberta Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇨🇦 CA

Who might be able to join this trial: - The person is a young adult between 17 and 27 years old at the time of joining the trial - The person has been admitted to or discharged from a psychiatric unit for psychosis at Alberta Health Services or Covenant Health in the Edmonton Zone within the past 12 months Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05527210 · University of Maryland, Baltimore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with schizophrenia or schizoaffective disorder according to standard diagnostic guidelines (DSM-5) - People between the ages of 18 and 60 - People whose treating psychiatrist considers their condition to be currently stable - People currently ta...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05550155 · University Hospital, Caen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇫🇷 FR

**Who might be able to join this trial:** - You are a man or woman between 18 and 65 years old - You have been diagnosed with schizophrenia or schizoaffective disorder based on standard medical guidelines (DSM 5.0) - You are currently taking at least one antipsychotic medication - You still experience hearing voices de...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05580211 · Scion NeuroStim Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2025
🇨🇦 CA

**Who might be able to join this trial:** - Adults aged 18 or older, whether currently hospitalised or attending as an outpatient - People who have been diagnosed with schizophrenia or schizoaffective disorder according to standard diagnostic guidelines (DSM-5) - People who are willing and able to give their own consen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05590637 · The University of Texas Health Science Center at San Antonio Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 August 2026
🇺🇸 US

Who might be able to join this trial: - People who are patients seen in the neurology clinic at UT Health San Antonio - People who have been diagnosed with psychosis related to Parkinson's disease or Dementia with Lewy Bodies - People whose doctor has determined they need to start taking an antipsychotic medication - P...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05617898 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇺🇸 US

Who might be able to join this trial: - People aged between 18 and 35 years old - People who have experienced their first episode of a psychotic illness that started within the last three years - People who have been diagnosed (using standard psychiatric guidelines called DSM-5) with schizophrenia, schizophreniform dis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05656469 · Parnassia Groep Not Applicable · 7 countries Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇩🇪 DE🇳🇱 NL🇷🇴 RO🇷🇸 RS🇪🇸 ES🇬🇧 GB🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with moderate or severe depression (including bipolar disorder currently in a depressive phase), an anxiety disorder (such as panic disorder or generalised anxiety disorder), or a psychotic disorder (such as schizophrenia or schizoaffective disorder),...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05661448 · Douglas Mental Health University Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2029
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with a psychotic disorder or a related mental health condition (such as affective or non-affective psychosis) - People who are currently being seen and treated by a clinician at one of the participating services - People whose symptoms are stable en...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05669742 · Tanta University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2026
🇪🇬 EG

**Who might be able to join this trial:** - Adults aged between 18 and 60 years old who have been diagnosed with schizophrenia and are currently being treated with the medication olanzapine. **Who may not be able to join:** - People who have any other condition involving inflammation in the body, such as heart or card...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05671185 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇹🇼 TW

**Who might be able to join this trial:** - People aged 20 years or older - People who are able to give informed consent to participate - People who have been diagnosed with schizophrenia or schizoaffective disorder according to the DSM-5 diagnostic guidelines - People who score 7 or higher on the Calgary Depression Sc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05703711 · University of Washington Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2027
Ghana

Who might be able to join this trial: - People who are 18 years of age or older - People who speak Twi or English - People who are currently staying as an inpatient at a prayer camp involved in the study - People who have been diagnosed with psychosis, mania, or depression Who may not be able to join: - People who hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05704582 · Ciusss de L'Est de l'Île de Montréal Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇨🇦 CA

Who might be able to join this trial: - People aged 18 or older who meet at least 4 of the DSM-5 criteria for Cannabis Use Disorder (a recognised pattern of problematic cannabis use — confirm with trial site for full details) - People who have been diagnosed with schizophrenia, schizoaffective disorder, or bipolar diso...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05731414 · University of Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇨🇦 CA

Who might be able to join this trial: - People aged between 18 and 65 years old - People who have been diagnosed with a schizophrenia-spectrum disorder - People who are able to read, write, and speak English Who may not be able to join: - People who have a neurodevelopmental disability (such as an intellectual disabil...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05748990 · Centre for Addiction and Mental Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇨🇦 CA

**Who might be able to join this trial:** **For people with a schizophrenia spectrum disorder (experimental group):** - People aged 17 to 45 years - People of any sex - People who have been diagnosed for the first time with one of the following conditions: schizophrenia, schizoaffective disorder, schizophreniform diso...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05763966 · Uppsala University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇸🇪 SE

**Who might be able to join this trial:** - People who have been diagnosed (using DSM-5 criteria) with one of the following: schizophrenia, schizophreniform psychosis, psychosis not otherwise specified, brief psychosis, schizoaffective syndrome, or delusional disorder — and whose psychotic symptoms and decline in day-...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05770375 · Anya Bershad, MD, PhD Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 60 years old - People who can understand spoken English well enough to follow the testing procedures - People who have been diagnosed with schizophrenia (based on the DSM-5 criteria, confirmed through a clinical interview) - People who have been clinically s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05778591 · University of California, Los Angeles Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - Adults between 18 and 60 years of age - People who can understand spoken English well enough to follow the testing procedures - People who scored below a certain threshold on a social network questionnaire used during screening (the trial site can explain this score in more detai...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05783063 · Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 40 years old - People who have been diagnosed with schizophrenia according to the DSM-5 diagnostic guidelines - People with a body mass index (BMI) of 25 or above, or who have gained more than 10% of their body weight since starting antipsychotic m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05796401 · Centre Hospitalier St Anne Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 15 December 2026
🇫🇷 FR

Who might be able to join this trial: - People aged 15 to 30 years, of any sex - People identified using a specific clinical assessment tool (called CAARMS) as either at high risk of developing psychosis, or within the first year after a first episode of psychosis diagnosis and care - People who are able to provide wri...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05805397 · Columbia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged between 18 and 65 years old - People who have been diagnosed with Schizophrenia or Schizoaffective Disorder according to standard diagnostic guidelines (DSM-5) - People who are medically and psychiatrically stable and being treated as an outpatient (not currently...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05813457 · Centre Hospitalier Universitaire de Saint Etienne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or brief psychotic disorder, as confirmed by standard diagnostic guidelines (DSM-5) - People who have never taken antipsychotic medication before, except possibly during their...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05823532 · Emory University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 March 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 55 years old who have been diagnosed with schizophrenia or schizoaffective disorder (as defined by standard diagnostic criteria) - People who are willing and able to sign a written consent form to participate - People whose blood test shows a C-reactive...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05830903 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇹🇼 TW

Who might be able to join this trial: - You have been diagnosed with schizophrenia according to standard diagnostic guidelines (DSM-5) - You are between 20 and 55 years old - You are motivated and interested in finding employment - You have an IQ score above 70, as measured by a standard intelligence test (confirm with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05858255 · Sykehuset i Vestfold HF Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇳🇴 NO

Who might be able to join this trial: - People who are able to give informed consent to take part in the study - People who can understand and speak a Scandinavian language - People who have been diagnosed with a schizophrenia spectrum disorder (such as schizophrenia, schizoaffective disorder, or schizophreniform disor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05890183 · University of California, Los Angeles Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have experienced their first episode of a psychotic illness that began within the past three years - People who have been diagnosed (using DSM-5 criteria) with schizophrenia, schizoaffective disorder, or schizophreniform disorder - People between 18 and 45 years of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05929352 · Yale University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇺🇸 US

**Who might be able to join this trial:** - People who hear voices and have been diagnosed with a psychotic disorder according to standard diagnostic guidelines (DSM-5) - People who hear voices at least once a day - People whose hallucinations score above a certain level on a standard clinical rating scale (PANSS P3 sc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05945602 · VA Office of Research and Development Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a chronic psychotic disorder (such as schizophrenia, schizoaffective disorder, or delusional disorder), OR people who are in good general mental and physical health with no active mental health condition. - People who can speak and read English...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05951660 · Zealand University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2025
🇩🇰 DK

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with schizophrenia or a related condition on the schizophrenia spectrum - You have at least one of the following: a diagnosis of diabetes, pre-diabetes shown by two blood tests taken at least 3 months apart, or obesity (a Bo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05956327 · LMU Klinikum Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇩🇪 DE

**Who might be able to join this trial:** - People who have been diagnosed with schizophrenia according to recognised medical diagnostic standards (ICD-10 and DSM-5) - People whose schizophrenia symptoms are at a relatively stable and low level, as measured by a standard symptom rating scale (a total score of 75 or bel...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05956951 · Fabio Ferrarelli Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** **For people with early schizophrenia:** - People aged 18 to 40 years old - People with a diagnosed schizophrenia-related condition (schizophrenia, schizophreniform disorder, or schizoaffective disorder) that was not caused by drug use, and who have not had a previously record...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05958875 · Dr. Inge Winter Phase 4 · 5 countries Recruiting
Recruiting Phase 4 Est. completion 30 June 2028
🇦🇹 AT🇩🇪 DE🇮🇹 IT🇪🇸 ES🇬🇧 GB

**Who might be able to join this trial:** - People aged 18 to 70 years old, whether currently in hospital or being treated as an outpatient. - People who are willing and able to sign a consent form before any part of the study begins (a legal guardian may co-sign if needed). - Women who could become pregnant must use...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05962216 · Dr. Albert Kar-Kin Chung Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
Hong Kong

**Who might be able to join this trial:** - People aged between 18 and 65 years old at the time of joining the trial - People who are able to read and communicate in English and/or Chinese - People who are able to give informed consent (meaning they can understand and agree to participate) - People who have been diagno...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05962879 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2027
🇺🇸 US

**Who might be able to join this trial:** - You are currently in 9th, 10th, 11th, or 12th grade and are between 14 and 19 years old - You have had at least one experience that could be described as psychotic (such as hearing or seeing things others don't, or having unusual beliefs) (confirm with trial site) - You are a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05973110 · The Royal Ottawa Mental Health Centre Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇨🇦 CA

**Who might be able to join this trial:** - People who have been diagnosed with a psychosis-spectrum disorder - People who are between 18 and 60 years old (inclusive) - People who are able to read and speak English - People whose symptoms are considered clinically stable, based on a specific symptom severity score (con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06003036 · Deepak K. Sarpal, M.D. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with schizophrenia or schizoaffective disorder according to current psychiatric diagnostic standards (DSM-5) - People between 18 and 50 years of age - People who have been taking the medication clozapine for at least 4 months - People who have previ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06005766 · University of Jyvaskyla Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇫🇮 FI

Who might be able to join this trial: **For patients:** - You are willing to take part in a scientific study - You have been diagnosed with a psychosis spectrum disorder - You can read and understand Finnish, as the questionnaires and tests are in Finnish **For people joining as healthy comparison participants (non-p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06021197 · China Medical University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇹🇼 TW

**Who might be able to join this trial:** - People who have been formally diagnosed with schizophrenia according to standard psychiatric diagnostic guidelines (DSM-5-TR). - People whose schizophrenia symptoms are in remission — meaning eight specific symptoms (such as hallucinations, delusions, and social withdrawal)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06036316 · Centre Psychothérapique de Nancy Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 23 January 2026
🇫🇷 FR

**Who might be able to join this trial:** **For everyone in the study:** - You are covered by a social security/health insurance scheme - You have been given full information about the study and agreed to take part by signing a consent form - If you are under 18, at least one parent or guardian has been informed about...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06045897 · Centre Hospitalier St Anne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2026
🇫🇷 FR

**Who might be able to join this trial:** - People aged between 15 and 30 years - People who meet a specific set of clinical criteria (called CAARMS criteria) for an "at-risk mental state," meaning they have mild to moderate early warning signs that may or may not develop into a more serious condition — there are two...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06048172 · Medicalschool Hamburg Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 May 2028
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with a psychotic disorder or a mood disorder that includes psychotic symptoms (such as hallucinations or delusions), based on standard diagnostic guidelines - You have also been diagnosed with Post-Traumatic Stress Disorder (PTSD), confirmed by a speci...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06058702 · Yale University Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2028
🇺🇸 US

"Who might be able to join this trial: - People who are between 21 and 60 years old Who may not be able to join: - People who have serious or unstable medical conditions, as identified through medical history, a structured psychiatric interview, information from others who know them, physical and lab tests, heart test...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06105151 · Vigonvita Life Sciences Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2025
🇨🇳 CN

Who might be able to join this trial: - Men aged 18 to 45 years old who weigh at least 50 kg, or women aged 18 to 60 years old who weigh at least 45 kg, with a body mass index (a height-to-weight ratio) between 19.0 and 26.0 - People whose general health check-ups, including physical examination, vital signs, blood tes...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06107764 · Mclean Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2029
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 55 years old - You have been diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder type I - You are able to read, speak, and understand English - You are considered by study staff to be able to complete all the study activities - Y...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06123897 · Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇨🇳 CN

Who might be able to join this trial: - People who have been clinically diagnosed with schizophrenia according to the ICD-11 diagnostic system. - People whose schizophrenia diagnosis has been confirmed through a structured research interview called the SCID-5-RV. Who may not be able to join: - People whose clinical as...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06127004 · Sormland County Council, Sweden Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2030
🇸🇪 SE

Who might be able to join this trial: - People who are over 18 years old - People who have been diagnosed with schizophrenia, delusional disorder, or a non-affective psychosis condition - People who live in the Region Sörmland, Region Västmanland, or Region Uppland areas of Sweden Who may not be able to join: - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06138054 · VA Office of Research and Development Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are currently living at the VA Greater Los Angeles Mental Health Residential Rehabilitation Treatment Program (also called the Domiciliary) - People between the ages of 18 and 65 - People who have been diagnosed with a psychotic illness (either one linked to mood d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06155682 · University of Maryland, Baltimore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2029
🇺🇸 US

**Who might be able to join this trial:** - People aged between 18 and 45 years old - People of any gender (male or female) - People who are able to understand the study information and agree to take part voluntarily - People who have been formally diagnosed with schizophrenia using a standardised diagnostic interview...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06174116 · University of Massachusetts, Worcester Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with schizophrenia or schizoaffective disorder, confirmed using a standard diagnostic interview - People who have been taking clozapine for at least 6 months - People whose antipsychotic medication dose has been stable for at least 1 month - Peo...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06191965 · Mclean Hospital Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 31 January 2027
🇨🇭 CH🇺🇸 US

Who might be able to join this trial: - You are between 18 and 35 years old (male or female) - You have been diagnosed with schizophreniform disorder, schizophrenia, schizoaffective disorder, or unspecified psychosis - You have been receiving treatment for psychosis for less than five years - Your symptoms are below a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06224530 · King's College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇬🇧 GB

**Who might be able to join this trial:** This trial has two groups of participants — people considered "at risk" of psychosis (CHR-P group), and healthy volunteers (HC group). **For the "at-risk" group:** - You are between 18 and 40 years old - You are able to understand the study and agree to take part - You have b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06229210 · Intra-Cellular Therapies, Inc. Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 28 April 2032
🇷🇸 RS🇺🇸 US

**Who might be able to join this trial:** - A parent or guardian must give written permission for their child to take part, and the patient themselves must also agree in writing to join the study - Boys or girls aged 13 to 17 years old with schizophrenia; boys or girls aged 10 to 17 years old with bipolar I or II diso...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06236048 · King's College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇬🇧 GB

**Who might be able to join this trial:** **Healthy volunteers:** - You have no history of any psychiatric (mental health) illness, as confirmed by a standard screening interview. **People with schizophrenia that responds to standard treatment:** - You have been diagnosed with schizophrenia according to standard inte...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06257056 · Bradley Lega Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are between 22 and 70 years old (men and women who are not pregnant) - People who have been formally diagnosed with schizophrenia as their primary condition, confirmed through a structured diagnostic interview - People who are generally in good physical health, wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06278532 · Lithuanian University of Health Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 11 December 2026
🇱🇹 LT

Who might be able to join this trial: - People who are between 18 and 65 years old - People who have been diagnosed with schizophrenia, schizoaffective disorder, or schizophrenia-like psychotic disorder (classified as F20, F25, or F21 under the international ICD-10 diagnostic system) - People who have signed a form giv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06286202 · Singapore Institute of Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇸🇬 SG

Who might be able to join this trial: - You have been diagnosed with schizophrenia or schizoaffective disorder based on standard medical guidelines (DSM-5). - You have completed at least 10 years of formal schooling, with English as the main language of instruction. - You are able to hold a conversation in English and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06313918 · Haukeland University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 September 2026
🇳🇴 NO

Who might be able to join this trial: - You have been diagnosed with a schizophrenia-spectrum disorder (a condition affecting how a person thinks, feels, and perceives reality) - You have been diagnosed with bipolar disorder (a condition involving extreme mood swings between highs and lows) - You are able to understand...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06330467 · Centre Psychothérapique de Nancy Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 August 2026
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who are enrolled in or covered by a French social security scheme - People who are fluent in French - People who are willing to take part in a psychological evaluation lasting between 1.5 and 3.5 hours - People who have a known...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06336382 · Jeremy Koppel Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - You are between 65 and 85 years old (male or female) - You have been diagnosed with a late-onset psychotic disorder, specifically either "very late-onset schizophrenia-like psychosis" or "delusional disorder" (confirm with trial site) - You have a caregiver who can provide inform...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06341517 · Indrit Begue Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 September 2026
🇨🇭 CH

**Who might be able to join this trial:** - People aged 18 to 65 years old who have been diagnosed with a schizophrenia spectrum disorder (such as schizophrenia, schizoaffective disorder, or a related psychotic disorder) based on standard diagnostic criteria (DSM-5) - People whose treating psychiatrist considers them...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06345963 · The University of Texas Health Science Center, Houston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2029
🇺🇸 US

Who might be able to join this trial: - People aged between 18 and 60 years old, of any gender - People who are able to read and sign a consent form agreeing to take part - People who have been diagnosed with a schizophrenia-spectrum disorder and who score above 10 on a specific assessment used to check their ability t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06351514 · Institute of Mental Health, Singapore Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 September 2026
🇸🇬 SG

Who might be able to join this trial: - People aged between 21 and 65 years old - People who have been diagnosed with schizophrenia or schizoaffective disorder - People who have been experiencing significant and ongoing negative symptoms (such as reduced motivation, emotional flatness, or withdrawal) for the past 6 mon...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06361407 · Centre Psychothérapique de Nancy Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 October 2027
🇫🇷 FR

**Who might be able to join this trial:** - You can be male or female - You must be between 18 and 60 years old (inclusive) - You must have read, dated, and signed the consent form before any trial procedures begin (a legal guardian or curator can do this where applicable) - You must be a member of, or covered by, a so...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06376734 · Brigham and Women's Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2029
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 65 years old - You can read, speak, and understand English well enough to give consent, complete questionnaires, and take part in treatment - You have a primary diagnosis of major depressive disorder (MDD), obsessive-compulsive disorder (OCD), generali...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06386588 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: - People aged between 18 and 45 years old - People who are fluent in English - People who are able to give their informed consent to participate For people with schizophrenia, these additional criteria also apply: - People who have a confirmed diagnosis of schizophrenia according...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06431009 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇩🇰 DK

Who might be able to join this trial: - People who are 15 years of age or older - People who have been diagnosed in the last 3 months with either a first episode of a schizophrenia-spectrum disorder or an "ultra-high risk" mental health condition (meaning early warning signs that may indicate a higher chance of develop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06456983 · Central Institute of Mental Health, Mannheim Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇩🇪 DE

Who might be able to join this trial: - People who have been diagnosed with schizophrenia (according to a standard medical classification system called DSM-5), have a symptom severity score above a certain level, and whose schizophrenia has not responded to a medication called clozapine — either because the medication...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06470516 · Sir Run Run Shaw Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with schizophrenia according to standard psychiatric diagnostic guidelines (DSM-5) - People aged 18 or older - People who are right-handed - People who are willing to take part and sign a consent form — or, if someone is unable to sign for them...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06482554 · Louisiana State University Health Sciences Center Shreveport Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People aged 18 to 65 who have been diagnosed with Schizophrenia, Schizoaffective Disorder, or a related psychotic disorder. - People who score above 35 on a symptom rating scale called the BPRS at the initial screening visit. - People who score above 32 on an apathy rating scale...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06484387 · University Hospital, Montpellier Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 8 November 2025
🇫🇷 FR

Who might be able to join this trial: **If you have schizophrenia:** - You have been officially diagnosed with schizophrenia according to standard diagnostic guidelines (DSM-V) - You are able to read, speak, and understand French - You are willing and able to give your informed consent to participate **If you are a h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06494124 · All India Institute of Medical Sciences, Bhubaneswar Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇮🇳 IN

Who might be able to join this trial: - People who have been diagnosed with Schizophrenia (using a standard international diagnostic system called ICD-10) for more than 2 years - People with moderate to severe symptoms, based on specific rating scale scores measured by clinicians (PANSS score above 75 and/or CGI-SCH sc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06502964 · Alto Neuroscience Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have had a diagnosis of schizophrenia for at least one year - People who have some level of cognitive impairment (difficulties with thinking, memory, or concentration) - People who have been on a stable dose of one or two antipsychotic medications for at least 8 w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06504290 · Vigonvita Life Sciences Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 July 2026
🇨🇳 CN

Who might be able to join this trial: **Healthy adults:** - Men aged 18 to 45 weighing at least 50kg, or women aged 18 to 60 weighing at least 45kg, with a Body Mass Index (BMI — a measure of body weight relative to height) between 19.0 and 26.0 - People whose general health checks — including physical examination, vi...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06505668 · All India Institute of Medical Sciences, Bhubaneswar Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇮🇳 IN

Who might be able to join this trial: - People who have been diagnosed with treatment-resistant schizophrenia (a form of schizophrenia that has not responded to standard treatments) and are currently taking the medication clozapine. - People aged between 18 and 60 years old, of any sex. - People whose resting heart rat...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06508450 · New York University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are between 18 and 34 years old - People who belong to a racial or ethnic group other than non-Hispanic White - People who are currently receiving services at the clinic partnering with this trial Who may not be able to join: - People who have cognitive impairments th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06556251 · Fundació Sant Joan de Déu Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 September 2026
🇪🇸 ES

Who might be able to join this trial: - You are between 18 and 40 years old - You have been identified as either having a first episode of psychosis, being in a critical period of psychosis, or being at very high risk of developing psychosis - You are already receiving community-based treatment through an early interve...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06562504 · Xiaofeng Ma Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with schizophrenia according to the DSM-5 (a standard medical diagnostic guide) - People aged 18 or older, of any gender, who have completed at least an elementary school level of education - People who are on a stable dose of antipsychotic med...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06562608 · Deepak K. Sarpal, M.D. Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2028
🇺🇸 US

Who might be able to join this trial: **For people with a psychiatric diagnosis:** - You have been formally diagnosed with schizophrenia or schizoaffective disorder, confirmed through a structured medical interview - You have been prescribed the medication benztropine or trihexyphenidyl for at least 6 months - You are...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06568081 · King's College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with a psychotic disorder or a related mood disorder with psychotic features (such as schizophrenia or similar conditions classified under ICD-10 codes F20–F39) - People who are looking for therapy to help with feelings of paranoia - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06573320 · Dr. Lutfi Kirdar Kartal Training and Research Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 August 2024
Turkey (Türkiye)

Who might be able to join this trial: - People who have been diagnosed with schizophrenia by a psychiatrist at the Turkish Ministry of Health Kartal Dr. Lütfi Kırdar City Hospital, using the standard DSM-5 diagnostic criteria - People who are currently taking clozapine at a therapeutic dose of between 300 and 500 mg pe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06574360 · China Medical University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇹🇼 TW

**Who might be able to join this trial:** - People who have been formally diagnosed with schizophrenia according to standard psychiatric guidelines (DSM-5) - People whose schizophrenia has not responded well enough to at least two different antipsychotic medications (not counting clozapine) - People who still have sym...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06580860 · mingjun Zhong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇨🇳 CN

Who might be able to join this trial: - People between 13 and 35 years old (or 14 to 35 years old if they have a healthy sibling participating) - People whose symptoms or illness started less than 24 months ago - People who have never taken medication for their condition, or who have taken medication for less than 2 we...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06581302 · Shanghai Jiao Tong University School of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with schizophrenia or another primary psychotic disorder, based on standard diagnostic guidelines (DSM-5). - You are between 18 and 55 years old. - Your symptoms score at least 60 on a standard psychiatric rating scale called the PANSS, which means you...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06585787 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company Phase 3 · 25 countries Recruiting
Recruiting Phase 3 Est. completion 24 November 2026
🇦🇷 AR🇧🇪 BE🇧🇷 BR🇧🇬 BG🇨🇳 CN🇭🇷 HR🇫🇷 FR🇩🇪 DE +17 more

Who might be able to join this trial: - People who are between 55 and 90 years of age at the time of the initial screening visit. - People who have been diagnosed with Alzheimer's disease based on the 2024 revised diagnostic criteria set by the Alzheimer's Association Workgroup. - People who have had a brain scan (MRI...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06588270 · Hospital de la Florida Dra. Eloiza Diaz Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2025
🇨🇱 CL

Who might be able to join this trial: - A psychiatrist has diagnosed the person with schizophrenia, confirmed using a standard international classification system (ICD-10). - The person is between 18 and 65 years old. - The person is receiving care as an outpatient (not currently staying in hospital for treatment). - T...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06595654 · Centre hospitalier de Ville-Evrard, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇫🇷 FR

**Who might be able to join this trial:** - People aged 18 years or older - People who have been diagnosed with schizophrenia according to a standard diagnostic system called DSM-V - People whose medication has remained stable for at least 4 weeks - People whose schizophrenia mainly involves "negative symptoms" (such a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06597864 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇳🇴 NO

Who might be able to join this trial: - People who have been diagnosed within the last 3 years with a condition such as schizophrenia, delusional disorder, or a related psychotic disorder (as classified under a specific medical coding system) - People who have been identified as being at risk of developing psychosis, b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06599372 · Dominique JANUEL Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇫🇷 FR

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have been diagnosed with schizophrenia according to a standard set of medical criteria called DSM-V - People who experience auditory hallucinations (hearing voices or sounds) that have not improved after trying two differen...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06613334 · Centre Hospitalier St Anne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 October 2026
🇫🇷 FR

Who might be able to join this trial: - People who are covered by a social security or other social protection scheme - People who have been diagnosed with schizophrenia according to the DSM-5 standard (diagnostic code F20) - People whose condition is currently in a stable state (no specific time period required for th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06617104 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 August 2025
🇹🇼 TW

**Who might be able to join this trial:** *Disease group (people with schizophrenia):* - People who have been diagnosed by a doctor with schizophrenia, whose condition is stable, and whose medication dose has not changed and who have not been admitted to a psychiatric acute care unit in the past 3 months - People aged...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06624462 · Bjorn H. Ebdrup Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇩🇰 DK

**Who might be able to join this trial:** - You have been diagnosed with a schizophrenia-related condition or bipolar disorder - You are currently taking antipsychotic medication - You are between 18 and 45 years old - You are legally able to make your own decisions - You are able to give your consent to take part in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06634446 · Centre Hospitalier St Anne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇫🇷 FR

Who might be able to join this trial: - People between the ages of 16 and 35, of any gender - People who are seeking help at one of the participating clinics or centres - People who have recently been diagnosed with a first episode of psychosis (assessed using a specific clinical tool called the CAARMS) within the past...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06634641 · Centre Hospitalier Universitaire, Amiens Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 September 2027
🇫🇷 FR

**Who might be able to join this trial:** - You are 18 years old or older and have been diagnosed with Parkinson's disease according to recognised medical guidelines (MDS 2015 criteria) - You are experiencing psychotic symptoms (such as hallucinations or delusions) that require treatment with a medication called Cloza...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06640803 · University of California, Davis Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇺🇸 US

Who might be able to join this trial: - You have been assessed as being at high risk of developing psychosis, based on a specific screening tool called the mini-SIPS - You are between 12 and 25 years old - You are currently receiving mental health care at one of six specific community mental health clinics involved in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06641297 · University of Maryland, Baltimore Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or psychosis NOS (a type of psychosis that doesn't fit neatly into other categories) - People between the ages of 15 and 45 - People who are able to give informed consent (mean...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06642675 · Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with schizophrenia based on recognised international medical guidelines (ICD-11). - Your diagnosis of schizophrenia has been confirmed through a structured research interview (a formal set of questions used to check the diagnosis). - You show notable "...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06649552 · Centre Psychothérapique de Nancy Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 13 January 2027
🇫🇷 FR

Who might be able to join this trial: - People being seen at one of three specific mental health centres in France (CLIP-Ado Nancy, CH Alpes-Isère, or CHRU Lille) for signs that may suggest a risk of developing psychosis, as assessed using specific clinical tools called the CAARMS scale and/or the SPI-CY scale. - Adole...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06650943 · Hospital de Basurto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇪🇸 ES

Who might be able to join this trial: - People who have been admitted to an Early Intervention Program (EIP) for psychosis. - People who have experienced their first episode of psychosis within the last 5 years. - People who have a diagnosis of a psychotic disorder or a mood disorder with psychotic symptoms, as classif...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06672588 · Centre for Addiction and Mental Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇨🇦 CA

Who might be able to join this trial: - People who are currently admitted to a hospital or attending as an outpatient. - People who are able to show they can understand and agree to take part in research, as measured by a standard assessment tool. - People who have been diagnosed with Schizophrenia or Schizoaffective D...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06673966 · Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with schizophrenia based on official medical guidelines (called ICD-11 criteria). - Your schizophrenia diagnosis has been confirmed using a structured medical interview called the SCID-5-RV. Who may not be able to join: - You have been diagnosed with, or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06674694 · Sichuan Kelun Pharmaceutical Co.,Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** *For healthy volunteers:* - Men and women between 18 and 65 years old at the time of signing consent, with at least one quarter of each group being of the same sex - People with a body mass index (BMI) between 19.0 and 26.0, and who weigh at least 45 kg (women) or 50 kg (men)...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06692530 · University Medical Center Groningen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2025
🇳🇱 NL

Who might be able to join this trial: - People aged 18 or older - People currently receiving treatment from CTP Veldzicht (a treatment centre in the Netherlands) - People who are seeking asylum in the Netherlands and are registered with the Centraal Opvang Asielzoekers (COA), which is the Dutch central asylum seeker re...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06700902 · Temple University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

Who might be able to join this trial: - You are currently enrolled in a 2- or 4-year college or university in the United States and can show a valid student ID card - You are experiencing serious mental health challenges, shown either by scoring 13 or higher on a specific mental health screening questionnaire (the K-6)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06728241 · Oslo University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇳🇴 NO

Who might be able to join this trial: - People between 17 and 65 years of age - People who are currently receiving treatment for psychosis at one of the participating hospital clinics - People who have been diagnosed with a schizophrenia-related condition, or a mood disorder that includes psychotic symptoms, according...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06729671 · University College Cork Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇮🇪 IE

**Who might be able to join this trial:** - People aged between 18 and 65 years old, including women of childbearing age - People who have been diagnosed with a form of psychosis (either affective or non-affective), as defined by specific international diagnostic codes (ICD-10 codes F20–30 and F32.3) - People who are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06745479 · Rutgers, The State University of New Jersey Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 50 years old - You are able to understand and agree to take part in the study on your own - You can communicate fluently in English - You are willing and able to follow the study's requirements, including signing a consent form and completing study task...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06758414 · VA Office of Research and Development Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2029
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with chronic back pain, as recorded in your medical records - Your pain is rated 4 or higher (out of 10) in terms of how severe it is or how much it interferes with your daily life - You have a diagnosed serious mental health condition — specifically s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06774417 · Columbia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People between 12 and 29 years old - People who live within 50 miles of a participating AMP-SCZ trial site in the United States - People who are able to complete a specific questionnaire (called the PQ-B) in English through an online screening platform run by Mental Health Am...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06774430 · Columbia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged between 12 and 29 years old - People who live within 50 miles of a participating trial location in the United States - People who are able to complete a specific questionnaire in English through an online screening platform run by Mental Health America (MHA) **Wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06781801 · Vastra Gotaland Region Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2029
🇸🇪 SE

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with a schizophrenia spectrum disorder (such as schizophrenia or a related condition) according to standard medical diagnostic codes (ICD-10 codes F20–F25 or F28–F29) - People who are able to give their own informed consent to parti...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06802939 · Shanghai Mental Health Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been clinically diagnosed with schizophrenia - People who are right-handed - People who have completed at least a primary school level of education - People who are able to read, understand, and sign a written consent form (for anyone under 18 years old, a guardia...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06821945 · Boryung Pharmaceutical Co., Ltd Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2027
🇰🇷 KR

Who might be able to join this trial: - You have been diagnosed with schizophrenia (based on standard medical guidelines called DSM-5), and your doctor believes a lower-than-usual starting dose of the medication olanzapine is more appropriate for you based on your overall health - You have had schizophrenia for more th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06835556 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 September 2029
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 65 years old. - You are able to communicate in English. - You have an estimated pre-illness IQ above 79, measured by a specific reading test (confirm with trial site). - You are willing and able to sign a written consent form to take part voluntarily. -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06839950 · Centre Hospitalier Esquirol Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 December 2027
🇫🇷 FR

**Who might be able to join this trial:** - Adults aged 18 to 65 years, of any gender - People who have been admitted to a closed inpatient psychiatric unit for less than 10 days - People who are enrolled in or covered by a social security system - People who have given free, informed, and written consent (or whose leg...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06856161 · Fraser Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 March 2027
🇨🇦 CA

**Who might be able to join this trial:** - People aged 19 or older - People who are able to give their own informed consent to take part in the study - People who have suspected, newly diagnosed, or established depression — or who are experiencing a first episode of psychosis, or have suspected or established schizoph...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06865937 · University of California, San Diego Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2028
🇺🇸 US

**Who might be able to join this trial:** - You are willing to take part and able to give your own consent to join the study, and are between 18 and 65 years old - You have been diagnosed with schizophrenia, schizoaffective disorder, bipolar I disorder, or major depression with a history of psychosis, based on a clinic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06870006 · Meyer Children's Hospital IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇮🇹 IT

"Who might be able to join this trial: - People who have been admitted to a psychiatry ward - People who are starting a medication that affects the heart's electrical activity (known as the QT interval) Who may not be able to join: - People who are over 18 years of age - People who have taken a medication that affects...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06872463 · Karolinska Institutet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇸🇪 SE

**Who might be able to join this trial:** *(For people being assessed for a first episode of psychosis)* - People who have received a diagnosis (assessed using a standard psychiatric tool called DSM-IV) of one of the following: schizophrenia, schizophreniform psychosis, psychosis not otherwise specified (NOS), brief p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06881810 · Central Institute of Mental Health, Mannheim Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2028
🇩🇪 DE

Who might be able to join this trial: - People aged 18 to 64 years. - People who are able to give written consent before joining the trial. - People who have been diagnosed with schizophrenia or another primary psychotic disorder (confirmed using a specific diagnostic interview called the MINI-DIPS-OA). - People who ha...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06882538 · Kastamonu University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 February 2025
Turkey (Türkiye)

Who might be able to join this trial: - People who have been diagnosed with schizophrenia - People who are registered with and continuing in a program called TRSM (confirm with trial site for full details on what this involves) - People who are willing to take part in work and training activities as part of the trial...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06882785 · Bristol-Myers Squibb Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 23 September 2028
🇯🇵 JP

**Who might be able to join this trial:** - You must have been formally diagnosed with schizophrenia through a thorough psychiatric assessment, using recognised diagnostic guidelines (DSM-5), confirmed by a structured interview called the MINI. - Your symptoms must fall within a specific range on a standard schizophren...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06886945 · IRCCS Centro San Giovanni di Dio Fatebenefratelli Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇮🇹 IT

Who might be able to join this trial: **All participants must meet these criteria:** - Having normal hearing - Having normal vision, or vision that is fully corrected with glasses or contact lenses **People joining as patients must also meet these criteria:** - Having a formal diagnosis of schizophrenia spectrum diso...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06887192 · MapLight Therapeutics Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇦🇷 AR🇧🇬 BG🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇷🇴 RO🇰🇷 KR🇺🇸 US

**Who might be able to join this trial:** - The person joining the trial must be willing and able to give written consent, or — if they are not able to do so — a legal representative must give written consent on their behalf, and the person themselves must also give their assent. - The person must have a diagnosis tha...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06888726 · Shanghai Mental Health Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are of Han Chinese ethnic background - You are 18 years old or older - You have at least 6 years of education, can fill out forms on your own, and have adequate vision and hearing to complete the required tests - You have been diagnosed with schizophrenia according to sta...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06894212 · Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 20 October 2026
🇯🇵 JP🇺🇸 US

Who might be able to join this trial: - People aged 18 to 65 years old at the time of signing the consent form. - People who have a reliable person in their life (such as a caregiver, family member, friend, case worker, or residential staff member) who can provide information about them. - People who are currently expe...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06911723 · University of Alabama at Birmingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 65 years of age - For the schizophrenia group: People who have been diagnosed with a psychotic disorder - For the healthy control group: People who do not currently have a mental health diagnosis as determined by a standard clinical interview (confirm wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06911931 · University of Rochester Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 to 65 years old - People with vision of 20/32 or better, including with glasses or contact lenses if needed - People who can speak English well enough to complete the study tasks and give informed consent - People diagnosed with schizophrenia, schizoaffective disor...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06929442 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - People who are between 18 and 30 years old - People who are enrolled as a first- or second-year student (freshman or sophomore) in an undergraduate degree program at the college or university where the trial is taking place - People who report having some unusual or suspicious th...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06936397 · Beykoz University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 August 2025
Turkey (Türkiye)

**Who might be able to join this trial:** **For people with schizophrenia:** - People who have been diagnosed with schizophrenia based on a standard set of diagnostic guidelines called DSM-5 - People aged between 18 and 55 years - People whose condition is currently stable, meaning no hospital stay or change in medica...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06944847 · State University of New York at Buffalo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

Who might be able to join this trial: - People who have been vaping or smoking cigarettes every day, or nearly every day, for at least 6 months - People whose cotinine level (a marker of nicotine use measured by a quick urine or saliva test) is 200 ng/mL or higher - People whose antipsychotic medication dose has stayed...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06945055 · Washington State University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2029
🇺🇸 US

**For Family Members / Support People:** Who might be able to join this trial: - You are a family member or support person of someone who has been enrolled in coordinated specialty care services for 6 months or less - You are 18 years of age or older - During a previous related study period (called FAMES), you did not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06957808 · King's College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 January 2027
🇬🇧 GB

**Who might be able to join this trial:** - People aged between 18 and 65 who have been diagnosed with schizophrenia according to standard diagnostic guidelines (DSM-5) - People whose antipsychotic medication dose has remained the same for at least one month - People who have been symptomatically stable with no relaps...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06958341 · Charite University, Berlin, Germany Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2031
🇩🇪 DE

**Who might be able to join this trial:** - People who are suspected of having a neuroimmunological disease (a condition where the immune system affects the nervous system) and for whom a spinal fluid test (lumbar puncture) has already been recommended as part of their diagnosis and treatment planning - People whose di...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06961968 · Vanda Pharmaceuticals Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 to 65 years old (inclusive), of any sex - People diagnosed with schizophrenia according to standard psychiatric diagnostic guidelines (DSM-5) - People who require ongoing psychiatric treatment Who may not be able to join: - People who have another psychiatric cond...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06963034 · Neurocrine Biosciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with schizophrenia as their primary condition - People who are currently experiencing a worsening or return of symptoms serious enough to require a hospital stay - People who are willing and able to stay in a hospital setting for the full durat...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06969755 · Northwell Health Phase 4 · 2 countries Recruiting
Recruiting Phase 4 Est. completion 30 July 2030
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 35 - People who have been diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder, as confirmed by a structured clinical interview (called the SCID-5) - People who are currently experiencing moderate or higher levels of certain...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06978803 · Douglas Mental Health University Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 October 2025
🇨🇦 CA

**Who might be able to join this trial:** - People who speak English or French (participants are paired with others who speak the same language) - People between 18 and 60 years old - People who have been diagnosed by their psychiatrist with schizophrenia or schizoaffective disorder, based on standard diagnostic guidel...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06978894 · Douglas Mental Health University Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇨🇦 CA

Who might be able to join this trial: - People who are 16 years of age or older - People who have been diagnosed with a psychotic disorder, such as schizophrenia, schizoaffective disorder, or a related condition, based on standard diagnostic guidelines (called DSM-5) - People who can speak and understand English or Fre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07001878 · Nova Scotia Health Authority Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 August 2026
🇨🇦 CA

Who might be able to join this trial: - People aged 18 to 25 years old who are enrolled in the Nova Scotia Early Psychosis Program Who may not be able to join: - People who currently have a stimulant use disorder (such as a problematic pattern of using drugs like cocaine or amphetamines) Important: Always verify elig...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07003529 · Centre Hospitalier Universitaire de Nīmes Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇫🇷 FR

**Who might be able to join this trial:** - You must have freely agreed to take part and signed a consent form - You must be covered by a health insurance plan - You must have been diagnosed with schizophrenia according to standard criteria (DSM-5), confirmed through a clinical interview - Your schizophrenia must have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07010614 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 65 years of age (men and women) - People with epilepsy that has not been controlled by treatment and who need a specific type of brain monitoring procedure — this applies to the intracranial EEG parts of the trial only - People who have received a forma...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07045142 · Central South University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old and have been diagnosed with schizophrenia according to standard medical guidelines (DSM-5) - Your symptoms and medications have been stable for more than 3 months, and you are taking no more than two antipsychotic medications (other medic...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07055204 · University Hospital, Toulouse Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇫🇷 FR

Who might be able to join this trial: - People who have been diagnosed with schizophrenia or schizoaffective disorder according to standard diagnostic guidelines (DSM-5 TR criteria) - People who have been clinically stable, meaning no full-time hospital stay related to schizophrenia in the past 3 months - People who ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07056894 · Nova Scotia Health Authority Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇨🇦 CA

Who might be able to join this trial: - People between 16 and 30 years of age who are already enrolled in an Early Intervention Services for Psychosis program in Nova Scotia, or the Psychosis Intervention Early Recovery program in Newfoundland. - People who have been diagnosed with a primary psychotic disorder, such as...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07058389 · Centre Hospitalier Universitaire de Saint Etienne Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇫🇷 FR

Who might be able to join this trial: - People diagnosed with schizophrenia who are between 18 and 55 years old - People who have ongoing, persistent negative symptoms of schizophrenia, measured by a specific symptom scale scoring above 7 (confirm with trial site for what this means in practice) - People who are regula...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07060066 · The University of Texas Health Science Center, Houston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2030
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 60 years of age, of any gender - People who are able to read and sign a consent form agreeing to take part - People who have been diagnosed with a schizophrenia-spectrum disorder and who score above 10 on a specific assessment of their ability to underst...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07060742 · Tobias Melcher Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 May 2027
🇨🇭 CH

Who might be able to join this trial: - People who have been diagnosed with a psychotic disorder - People who are aged 55 years or older - People who are able to sign a consent form agreeing to take part - People who score 20 or higher on a standard memory and thinking test called the MoCA - People who are able to stan...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07061288 · Bristol-Myers Squibb Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 21 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been formally diagnosed with schizophrenia, confirmed through a psychiatric assessment using recognised diagnostic tools and guidelines. - People whose schizophrenia symptoms are rated as moderate or below on two standard measurement scales, at both an initia...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07085923 · Madeleine Elisabeth Angelsen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2028
🇳🇴 NO

**Who might be able to join this trial:** - People who have been diagnosed with a schizophrenia spectrum disorder or bipolar affective disorder - People who are currently taking antipsychotic medication (older or newer types) or lithium - People with a Body Mass Index (BMI) of 27 or higher (this means a body weight con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07091344 · Fundació Sant Joan de Déu Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇪🇸 ES

**Who might be able to join this trial:** - Adults aged 18 years or older - People who have been diagnosed with a schizophrenia spectrum disorder according to standard diagnostic guidelines (DSM-5) - People who have been hearing voices persistently for at least 3 months, at a level that meets a specific threshold on a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07098169 · University of California, San Diego Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
🇺🇸 US

**Who might be able to join this trial:** - People who are willing to take part and are able to give informed consent, as assessed by a short capacity test called the UBACC - People aged 18 to 65 - People who have been diagnosed with schizophrenia or schizoaffective disorder (based on DSM-5 criteria), confirmed throug...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07101094 · Bristol-Myers Squibb Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2029
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older at the time they enter the study. - People who have received a confirmed diagnosis of schizophrenia before joining the study. - People for whom a doctor has written an initial prescription for the medication xanomeline and trospium chloride...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07105111 · Neurocrine Biosciences Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder for at least 3 months before the screening appointment - You have been diagnosed with at least mild tardive dyskinesia (invo...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07113119 · Aristotle University Of Thessaloniki Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 August 2025
🇬🇷 GR

Who might be able to join this trial: - People who are adults (18 years or older) - People who are currently admitted to hospital with a diagnosis of a psychotic syndrome - People whose medication has remained the same and steady for a period of time - People whose psychosis is currently considered under control - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07114874 · Neurocrine Biosciences Phase 3 · 4 countries Recruiting
Recruiting Phase 3 Est. completion 1 December 2031
🇧🇬 BG🇷🇴 RO🇷🇸 RS🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with schizophrenia as their primary condition - People who are able to stop taking certain medications before the study begins, including antipsychotics, if they are currently taking any - People who have a stable, secure living situation **Who...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07119268 · Indiana University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who are currently enrolled in college - People who are fluent in English - People who score 7 or higher on a screening tool called the Prodromal Questionnaire-Brief, which checks for certain early mental health experiences (con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07122531 · Université de Sherbrooke Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 April 2027
🇨🇦 CA

**Who might be able to join this trial:** - People who have been referred to, or have referred themselves to, the PEP (First Episode Psychosis) Clinic in the Estrie region, either as an outpatient or as someone staying in hospital. - People who have been taking a second- or third-generation antipsychotic medication at...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07122895 · China Medical University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2029
🇹🇼 TW

**Who might be able to join this trial:** - You have been officially diagnosed with schizophrenia according to standard diagnostic guidelines (DSM-5) - Your mental health has been stable for at least 6 months before the study starts, and your main symptoms are "negative symptoms" (such as low motivation, reduced emotio...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07139171 · Tianjin Anding Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are a healthy volunteer who matches other participants in the study in terms of sex, age, and education level - None of your close relatives (parents, siblings, children, grandparents, aunts, or uncles) have been diagnosed with a mental health condition - You are of Han C...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07176468 · Anhui Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 September 2026
🇨🇳 CN

Who might be able to join this trial: - People between 18 and 60 years old, of any gender - People who have been diagnosed with schizophrenia according to the DSM-5 diagnostic guidelines - People whose antipsychotic medication was started, switched, or had its dose changed within the last 3 days - People who are able t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07184619 · Newron Pharmaceuticals SPA Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇮🇳 IN🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older. - If you are female, you have a negative pregnancy test at the start of the study, are not breastfeeding, and agree to use appropriate birth control (unless you cannot become pregnant). - You have been diagnosed with schizophrenia according to...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07185815 · Mapi Pharma Ltd. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇮🇳 IN🇮🇱 IL

**Who might be able to join this trial:** - People who have been diagnosed with schizophrenia, bipolar I disorder, or major depressive disorder according to standard diagnostic guidelines (applies to groups 1 and 2 of the trial only) - People whose condition is currently stable — meaning no recent worsening, and whose...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07191483 · Kynexis B.V. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been formally diagnosed with schizophrenia as their primary psychiatric condition - People whose schizophrenia has been in a stable, non-crisis phase for at least 8 weeks before the screening appointment, as judged by the study doctor - People who have had a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07196423 · University of Nottingham Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇬🇧 GB

Who might be able to join this trial: **For people with a first episode of psychosis (Studies 1a and 1b):** - People aged 18 to 55 years old - People who are able to understand the study and are willing to sign a consent form - People who are fluent in English, as all tasks and questionnaires are in English - People w...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07196462 · Vanderbilt University Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: **For people with a psychotic disorder:** - People aged between 18 and 65 years old - People who have been diagnosed with a psychotic disorder, confirmed using a standard diagnostic interview called the SCID - People who are currently using cannabis, at a level of at least 2 out o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07213492 · McMaster University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇨🇦 CA

**Who might be able to join this trial:** - People who are between 18 and 35 years old - People who have been diagnosed with bipolar disorder within the last 24 months - People who experienced psychosis and/or had limited awareness of their illness at the time of joining the study - People who can understand and speak...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07217652 · Kai Hwang Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2030
🇺🇸 US

**Who might be able to join this trial:** - You have no history of any brain, nerve, mental health, or other medical conditions that could affect your thinking or memory - You are not taking certain medications such as benzodiazepines, strong opioid painkillers, or other drugs that could affect your mental performance...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07221877 · Bristol-Myers Squibb Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 December 2027
🇺🇸 US

Who might be able to join this trial: - Adults between 18 and 65 years old, both male and female, who have been diagnosed with schizophrenia confirmed through a psychiatric evaluation using standard diagnostic tools (DSM-5 and MINI assessment) - People whose schizophrenia symptoms are rated as moderate or below on stan...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07225712 · Otsuka Pharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2028
🇯🇵 JP

Who might be able to join this trial: - People who are Japanese, male or female, and aged 18 or older at the time of signing the consent form - People who have been diagnosed with schizophrenia according to a standard diagnostic system called the DSM-5 - People whose condition has been considered clinically stable by t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07227818 · Neurocrine Biosciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2029
🇺🇸 US

Who might be able to join this trial: - People who have been formally diagnosed with schizophrenia through a full psychiatric assessment using the current standard diagnostic guidelines (DSM-5-TR). - People whose schizophrenia was first diagnosed at least one year before the screening appointment for this trial. - Peop...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07230652 · Luye Pharma Group Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** *For healthy participants:* - You are willing to sign a consent form to take part in the study. - You are a man or woman between 18 and 45 years old. - You weigh at least 50 kg (if male) or at least 45 kg (if female), and your BMI (a measure of body weight relative to height)...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07231497 · University of Minnesota Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 April 2030
🇺🇸 US

**Who might be able to join this trial:** - You are comfortable reading, speaking, and understanding English - Your score on a thinking and memory test suggests an IQ of 70 or above - You have been living in the community (not in a hospital or inpatient facility) for at least one month before joining the study - Your m...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07234708 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇪🇸 ES

Who might be able to join this trial: - Adults aged 18 years or older, of any gender - People who have been diagnosed with a schizophrenia spectrum disorder or another psychotic disorder, as defined by a standard psychiatric diagnostic guide (DSM-5) - People whose symptoms include delusions rated at a certain level of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07242586 · Nikolai Albert Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇩🇰 DK

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with a condition on the schizophrenia spectrum (such as schizophrenia or a related condition) - You have PTSD symptoms that score above 31 on a standard checklist called the PCL-5 (confirm with trial site) - You are curre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07263022 · University of Minnesota Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 April 2030
🇺🇸 US

**Who might be able to join this trial:** - People who are between 18 and 35 years old - People who have been diagnosed with a psychosis-related illness (such as schizophrenia, schizoaffective disorder, schizophreniform disorder, psychosis not otherwise specified, bipolar disorder with psychosis, or major depressive d...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07265180 · Charite University, Berlin, Germany Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇩🇪 DE

Who might be able to join this trial: - You must be willing to give your consent to take part in the study - You must have a diagnosis of schizophrenia or a related condition (on the schizophrenia spectrum) - You must have mild to moderate symptoms (such as hallucinations or delusions), not severe ones, as measured by...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07288333 · Neurocrine Biosciences Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇧🇬 BG🇬🇧 GB

Who might be able to join this trial: - People who are between 18 and 55 years old - People who have been diagnosed with schizophrenia for at least 1 year before the screening visit - People who are currently experiencing a worsening or return of schizophrenia symptoms that started less than 2 months before screening a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07288567 · Bristol-Myers Squibb Phase 3 · 5 countries Recruiting
Recruiting Phase 3 Est. completion 18 December 2029
🇦🇷 AR🇨🇴 CO🇯🇵 JP🇷🇴 RO🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with schizophrenia according to a standard diagnostic guide (DSM-5-TR), confirmed through a structured clinical interview, and who are experiencing symptoms of psychosis at the time of screening. - People whose symptoms score at least 70 on a st...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07290738 · The University of Texas Health Science Center, Houston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2030
🇺🇸 US

Who might be able to join this trial: - People who are able to give written consent to participate. - People who have been diagnosed with a schizophrenia-spectrum disorder and who score above 10 on a test used to assess their ability to understand and consent to research. - People who are currently receiving care from...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07306468 · Çankırı Karatekin University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
Turkey (Türkiye)

Who might be able to join this trial: - You are willing to volunteer to take part in the trial - You are between 18 and 65 years old Who may not be able to join: - You have a breathing, heart, neurological, or bone/joint condition that could affect how well you breathe or how much physical activity you can do - You ha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07309172 · Ole Köhler-Forsberg Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2027
🇩🇰 DK

**For patients with a first-episode of schizophrenia (FES):** Who might be able to join this trial: - People aged 18 to 35 years old - People who have been diagnosed with first-episode schizophrenia (under the diagnosis code F20) - People who are able to give their agreement to participate, both verbally and in writin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07316803 · Centre hospitalier de Ville-Evrard, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with a serious mental illness, such as schizophrenia, bipolar disorder, or major depressive disorder - People who are currently single - People who are motivated to work on their social and romantic relationships and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07343193 · University Hospital, Strasbourg, France Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇫🇷 FR

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with a psychotic disorder or a related condition - People who have been on long-term antipsychotic medication, are currently in a stable condition, and have agreed to or asked for a gradual reduction of thei...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07344948 · Neurosterix Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 May 2026
🇺🇸 US

**Who might be able to join this trial:** - Men, or women who are not pregnant or breastfeeding, aged 18 to 55, who either cannot become pregnant, live a completely abstinent lifestyle, or agree to use an approved form of contraception - For certain parts of the trial (Part 1a/b and Part 2 Cohort 7): People whose body...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT07350954 · Lucy Jonas Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇬🇧 GB

Who might be able to join this trial: - You are between 16 and 18 years old - You are currently seeking help from a Child and Adolescent Mental Health Service (CAMHS) - You have scored 11 or above on a specific questionnaire that measures paranoia called the R-GPTS Scale B (confirm with trial site) - You can understand...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07360665 · University of Trás-os-Montes and Alto Douro Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇵🇹 PT

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with psychosis by a doctor - You are currently receiving your antipsychotic medication as a long-acting injection (a shot given every few weeks instead of daily pills) - You are currently being seen and monitored at the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07363577 · LB Pharmaceuticals Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are able to give written consent to participate in the study - People who are willing to stay in hospital for the entire duration of the study - People who have been diagnosed with schizophrenia according to DSM-5 diagnostic standards - People whose Body Mass Index...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07378150 · Kutahya Health Sciences University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 January 2026
Turkey (Türkiye)

Who might be able to join this trial: - People who have been diagnosed with schizophrenia - People who are 18 years of age or older - People who have completed at least primary school education - People who have been following their prescribed treatment plan as directed - People who are currently taking medication as p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07379827 · Bristol-Myers Squibb Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 June 2028
🇺🇸 US

**Who might be able to join this trial:** - You (or your caregiver or legal guardian) must be willing and able to sign a consent form agreeing to take part in the study. - You must be 18 years old or older and able to take part in regular medical care and follow-up visits, in your doctor's opinion. - You must have sch...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07383324 · University of Ottawa Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2027
🇨🇦 CA

Who might be able to join this trial: - People who speak English or French - People who are able to give their own consent to take part in a study - People who have been diagnosed with schizophrenia or schizoaffective disorder, as well as people who have not been diagnosed with either of these conditions Who may not b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07395206 · Charite University, Berlin, Germany Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇩🇪 DE

Who might be able to join this trial: - You have been diagnosed with Schizophrenia or Schizoaffective Disorder (these are specific mental health conditions) - You are between 18 and 65 years old - You can speak and understand German well enough to participate - You are able to use a smartphone Who may not be able to j...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07397975 · Philipp Homan Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 31 January 2029
🇨🇿 CZ🇮🇪 IE🇳🇱 NL🇳🇴 NO🇨🇭 CH Turkey (Türkiye)

**Who might be able to join this trial:** **Healthy participants:** - People aged 18 to 65 years old. - People who are not currently taking prescription medications on a regular basis. - People who speak and understand English, German, Dutch, French, Czech, or Turkish fluently (or at an equivalent level). - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07398365 · University of Edinburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇬🇧 GB

Who might be able to join this trial: - You are an adult aged between 18 and 65 years old - You have been admitted to a GAP ward (confirm with trial site) during the time the trial is recruiting Who may not be able to join: - You have been admitted to a ward other than a GAP ward, such as a forensic psychiatry unit, a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07410507 · Eli Lilly and Company Phase 2 · 7 countries Recruiting
Recruiting Phase 2 Est. completion 1 November 2027
🇦🇷 AR🇧🇷 BR🇨🇳 CN🇮🇳 IN🇯🇵 JP🇹🇼 TW🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with schizophrenia according to established diagnostic criteria - People who are currently on a stable medication routine for schizophrenia - People whose schizophrenia has lasted more than 6 years and who have had at least one return of symptoms (r...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07419321 · Icahn School of Medicine at Mount Sinai Not Applicable · 4 countries Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇳🇱 NL🇪🇸 ES🇬🇧 GB🇺🇸 US

Who might be able to join this trial: **For people with schizophrenia or a related condition:** - You have been diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or a similar condition (but not a psychotic disorder caused only by substance use) - You are between 40 and 70 years old at...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07423546 · New York State Psychiatric Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 50 years old at the time of screening - People who are able to understand the study procedures and agree to take part voluntarily - People who have been diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder - People who are no...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07428460 · Douglas Mental Health University Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇨🇦 CA

Who might be able to join this trial: - People who have been diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder - People whose illness has lasted for 6 months or longer - People who have significant "negative symptoms" (such as reduced motivation, emotion, or speech — confirm with tria...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07434479 · Manhattan Psychiatric Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to give written consent to take part, attend study visits, and follow study-related requirements - People who are fluent in written and spoken English, confirmed by being able to read and understand the consent form - People who are currently...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07441928 · The Hong Kong Polytechnic University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
Hong Kong

**Who might be able to join this trial:** - People who have been diagnosed with schizophrenia or schizoaffective disorder and have been followed up by a doctor or service for at least one year - People who have been taking antipsychotic medication regularly for at least three months with good adherence to their prescr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07446478 · Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 50 years old - People who have been diagnosed with schizophrenia according to standard medical guidelines (DSM-5), confirmed through a structured clinical interview - People whose schizophrenia was diagnosed no more than 8 years ago - People who ar...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07450027 · Elazığ Mental Health and Diseases Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
Turkey (Türkiye)

Who might be able to join this trial: **Group 1 – People with Methamphetamine Use Disorder (MUD):** - People who have been formally diagnosed with Methamphetamine Use Disorder based on recognised diagnostic standards (DSM-5-TR) - People who have not taken any medications for at least one month before entering the stud...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07455929 · Charite University, Berlin, Germany Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇩🇪 DE

**Who might be able to join this trial:** - People who have been diagnosed with a Schizophrenia Spectrum Disorder, confirmed by previous medical records, using standard diagnostic guidelines (ICD-10 or DSM-V) - People who are currently receiving psychiatric care as an outpatient (not admitted to hospital) - People aged...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07459647 · MapLight Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2030
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to give informed consent for all parts of the study - People who have been diagnosed with schizophrenia according to standard diagnostic guidelines (DSM-5), confirmed through a structured clinical interview - People whose doctor (the investiga...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07459660 · MapLight Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2029
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part, or if you are not able to do this yourself, a trusted legal representative can sign on your behalf and you can show your agreement in another way. - You have already completed the full double-blind treatme...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07467993 · Novartis Pharmaceuticals Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 29 July 2027
🇧🇬 BG🇺🇸 US

Who might be able to join this trial: - People who are between 18 and 65 years old at the time of initial screening - People who are able to understand the study and agree to take part in it - People who have been formally diagnosed with schizophrenia, confirmed through a detailed psychiatric assessment using recognise...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07469384 · Nathan Kline Institute for Psychiatric Research Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2030
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 55 years old, of any gender - People who are able to understand and willing to sign a consent form agreeing to take part - People who are no more than moderately unwell (not severely ill) - People who have been diagnosed with schizophrenia or schizoaffectiv...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07479758 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are between 18 and 45 years old at the time of joining the trial - Both men and women are eligible to participate - For people with a mental health condition: those who have been formally diagnosed with major depression, schizophrenia, or bipolar disorder according...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07483294 · Northwell Health Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2029
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a first-time psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, psychotic disorder not otherwise specified, bipolar disorder with psychosis, or major depressive disorder w...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07493551 · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 65 years old (inclusive). - People who have been diagnosed with schizophrenia according to ICD-10 diagnostic criteria before the screening stage. - People who meet specific weight requirements: male participants weighing at least 50.0 kg, and female participants...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07509125 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2029
🇧🇪 BE

Who might be able to join this trial: **Healthy volunteers (Work Package 1):** - People aged between 18 and 90 years old (the study aims to recruit 15 people aged 18–50 and 25 people aged 50–90) - People judged to be in good general health by the study doctor, based on medical history, physical check-up, and lab tests...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07557368 · Shanghai Mental Health Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇨🇳 CN

Who might be able to join this trial: - People who are registered in the Shanghai Mental Health Information Management System and are currently admitted to a designated district-level mental health centre ward - People who have been diagnosed with schizophrenia according to the International Classification of Diseases...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07557381 · Shanghai Mental Health Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are registered in the Shanghai Mental Health Information Management System and are currently staying in a designated district-level mental health center ward - You have been diagnosed with schizophrenia according to the ICD-10 international diagnostic guidelines - You are...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07559084 · Shanghai Mental Health Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
🇨🇳 CN

Who might be able to join this trial: - People who are current or former patients at the Department of Psychiatry, Shanghai Mental Health Center (either attending outpatient appointments or admitted to the ward) - People who have been diagnosed with first-episode schizophrenia according to a standard diagnostic intervi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07565428 · Minerva Neurosciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 55 with a body mass index (BMI) of 35 or below, of any gender, who have given their informed consent and are understood by the investigator to be able to follow the study requirements. - People who have been formally diagnosed with schizophrenia according t...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07569471 · University of Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2027
🇨🇦 CA

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, or Delusional Disorder (based on self-report) - People who are currently experiencing symptoms related to psychosis, as measured by a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07606014 · University Medical Center Groningen Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 May 2029
🇳🇱 NL

**Who might be able to join this trial:** - People who are about to start, or who have started within the last 8 weeks, taking one of these antipsychotic medications for psychosis: olanzapine, quetiapine (at a full therapeutic dose, not a low dose used only as a sleep aid), clozapine, or risperidone - People aged betw...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07615426 · Janssen Research & Development, LLC Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 21 June 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with schizophrenia (confirmed through a specific psychiatric interview called the MINI) and whose condition is currently stable - People who are taking one atypical antipsychotic medication only, at a dose that has not recently changed - People...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07616999 · The University of Hong Kong Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - People who took part in a previous clinical trial (registered as NCT00334035) that looked at whether continuing or stopping medication affected the chances of relapse during a first episode of psychosis - People who had been diagnosed with schizophrenia or a related psychosis con...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07621549 · Far Eastern Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇹🇼 TW

**Who might be able to join this trial:** - You are between 18 and 65 years old - You are any gender (both males and females can apply) - You have been diagnosed with schizophrenia based on standard diagnostic guidelines, with a symptom score that is not considered very high (confirm with trial site) - Your psychiatric...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07645443 · Stephanie Mehl Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇩🇪 DE

Who might be able to join this trial: - You are between 16 and 35 years old - You have been diagnosed with an early psychotic episode (your first episode of psychosis occurred within the last 5 years), confirmed through a structured clinical interview - Your diagnosis falls within the schizophrenia spectrum or another...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07671261 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - People who have been formally diagnosed with schizophrenia according to standard international diagnostic guidelines (ICD-10). - People who are male or female, aged between 18 and 55 years, with stable basic health signs such as heart rate and blood pressure. - People who are cur...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07680946 · TG Therapeutics, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - People with a primary diagnosis of schizophrenia. - People whose schizophrenia has not responded well to previous treatments (sometimes called "treatment-resistant" schizophrenia). - People who need antipsychotic medication and are currently receiving standard treatment for their...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07682935 · Firat University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 July 2026
Turkey (Türkiye)

Who might be able to join this trial: - Adults aged 18 years or older - People who are able to communicate verbally - People who have been diagnosed with schizophrenia - People who are able to provide written consent to participate Who may not be able to join: - People who have other mental health conditions in additi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07692984 · Abant Izzet Baysal University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
Turkey (Türkiye)

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with a Schizophrenia Spectrum Disorder, another Psychotic Disorder, or Bipolar Disorder, based on a standard set of medical guidelines called DSM-5 - People who have been regularly seen and monitored at the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07696000 · DINA KEUMALA SARI Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇮🇩 ID

**Who might be able to join this trial:** - Adults between 18 and 60 years of age - People who have been diagnosed with schizophrenia based on standard diagnostic criteria (DSM-5) - People who have been on a stable antipsychotic medication for at least 4 weeks before joining the trial - People who are currently admitte...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07701343 · Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 50 years who have been diagnosed with schizophrenia, confirmed using a standard structured interview process. - People who score below a certain threshold on a specific memory and thinking test called the MATRICS Consensus Cognitive Battery (MCCB), particularly...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07703670 · Northwell Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2031
🇺🇸 US

Who might be able to join this trial: - People who are experiencing their first episode of psychosis and have been diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or a similar psychosis condition according to standard diagnostic guidelines - People who are currently experiencing moder...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07713849 · University of Chicago Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 May 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, major depressive disorder with psychotic features, schizophreniform disorder, or psychosis that does not fit a specific category. - People whose psychotic d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07716969 · Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇩🇰 DK

Who might be able to join this trial: - People who are 18 years of age or older - People who are currently receiving treatment at an OPUS treatment centre in the Capital Region or Region Zealand - People who started their OPUS treatment within the last 9 months - People who are suspected to have a psychotic disorder on...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Schizophrenia. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

SANE Australia supports people affected by complex mental illness, including schizophrenia.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.